Cleary, James M.
McRee, Autumn J.
Shapiro, Geoffrey I.
Tolaney, Sara M.
O’Neil, Bert H.
Kearns, Jeffrey D.
Mathews, Sara
Nering, Rachel
MacBeath, Gavin
Czibere, Akos
Sharma, Sunil
Korn, W. Michael
Funding for this research was provided by:
Merrimack Pharmaceuticals
Article History
Received: 29 August 2016
Accepted: 9 October 2016
First Online: 16 November 2016
Compliance with ethical standards
:
: JC reports research funding to his institution from Merrimack Pharmaceuticals, Taiho Oncology, Merck, Roche, Abbvie, Precision Biologics, and Bristol Myers Squib. He was a paid consultant with Agios Pharmaceuticals. GI was a paid consultant for Lilly, GI Therapeutics, EMD Serono, Chugai, and Millennium. He has also received research funding from Pfizer. ST reports research funding to her institution from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, and Novartis. SM, RN, GM, JK and AC are all employees of Merrimack Pharmaceuticals. WMK is a paid consultant for Merrimack Pharmaceuticals. AM, BO, and SS report no conflicts of interest.
: This study was sponsored by Merrimack Pharmaceuticals.
: All procedures performed in human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Written informed consent was obtained from all individual participants included in the study.
: Merrimack Pharmaceuticals, Inc.